TOP > 外国特許検索 > STOMACH CANCER BIOMARKER AND USE THEREOF

STOMACH CANCER BIOMARKER AND USE THEREOF

外国特許コード F200010146
整理番号 (S2018-0509-N0)
掲載日 2020年6月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP021098
国際公開番号 WO 2019244575
国際出願日 令和元年5月28日(2019.5.28)
国際公開日 令和元年12月26日(2019.12.26)
優先権データ
  • 特願2018-118340 (2018.6.21) JP
発明の名称 (英語) STOMACH CANCER BIOMARKER AND USE THEREOF
発明の概要(英語) The present invention addresses the problem of providing a biomarker that is highly practical, specific to stomach cancer, and is less invasive. The stomach cancer biomarkers identified were hsa-miR-6807-5p, hsa-miR-6856-5p, and hsa-miR-575as. According to the present invention, the occurrence of stomach cancer is determined using the expression levels of these microRNA molecules as indicators.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is the gold standard of diagnosis of gastric cancer, upper gastrointestinal endoscopy and associated tissue diagnosis is, from the expensive and highly aggressive, normal and on the screening test of the examination and the like and is not recommended. On the other hand, the upper gastrointestinal tract examination of the stomach at the site of a contrast medium examination is now widely introduced, the decrease in mortality by examination of the stomach is not scientific demonstrated. In addition, a contrast medium examination is the gastrointestinal tract, the subject and at the position after taking barium, barium and the degree of expansion deformation of the walls by storing, by the state of the deposited barium, gastrointestinal lesions and pick up, such as gastric tumor component remains on the surface of the representation of the early cancer is difficult.
CEA or the like in the blood serum tumor marker CA19-9 is used, these molecules are described, from a low sensitivity (gastric cancer diagnosis sensitivity of the CEA in 24.0%, CA19-9 has been reported in 27.0%) as a diagnostic marker for use is not recommended. In addition, biomarkers specific gastric cancer are under development (for example, Patent Document 1, 2), and clinical application on an example. In addition, biomarkers of the present invention the molecule are listed below in the literature (JP-3-7, non-patent document 1).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • SHIMURA TAKAYA
  • IWASAKI HIROYASU
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close